Rigel Pharmaceuticals, Inc.
RIGL
$42.58
$1.794.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 33.81% | -15.41% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 33.81% | -15.74% | |||
| Cost of Revenue | 38.10% | -2.15% | |||
| Gross Profit | 32.16% | -19.99% | |||
| SG&A Expenses | 6.50% | 2.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.46% | 0.65% | |||
| Operating Income | 98.36% | -48.71% | |||
| Income Before Tax | 102.32% | -48.68% | |||
| Income Tax Expenses | 109.62% | 101.22% | |||
| Earnings from Continuing Operations | 99.79% | -96.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 99.79% | -96.77% | |||
| EBIT | 98.36% | -48.71% | |||
| EBITDA | 95.67% | -47.49% | |||
| EPS Basic | 98.40% | -96.81% | |||
| Normalized Basic EPS | 100.91% | -49.25% | |||
| EPS Diluted | 100.00% | -96.75% | |||
| Normalized Diluted EPS | 103.51% | -48.40% | |||
| Average Basic Shares Outstanding | 0.70% | 1.12% | |||
| Average Diluted Shares Outstanding | -0.59% | -0.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||